Tempus Announces 31 Abstracts for AACR 2026

Got story updates? Submit your updates here. ›

Tempus AI, a leading technology company in the field of AI-powered precision medicine, has announced that 31 of its research abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. The conference is a premier event for cancer researchers and clinicians to share the latest advancements in oncology.

Why it matters

Tempus's strong presence at AACR 2026 underscores the company's commitment to driving innovation in precision cancer care through the application of advanced AI and data analytics. The accepted abstracts are likely to showcase Tempus's progress in developing novel diagnostic tools, treatment strategies, and patient management solutions that leverage the power of data and technology to improve outcomes for cancer patients.

The details

The 31 Tempus abstracts accepted for presentation at AACR 2026 will cover a range of topics, including the use of AI-powered biomarker discovery, the development of personalized treatment plans, and the optimization of clinical trial design. These research findings are expected to contribute to the ongoing efforts to advance the field of precision oncology and provide more targeted and effective care for cancer patients.

• The AACR Annual Meeting 2026 will take place from April 12-16, 2026.

What’s next

The presentation of Tempus's research at AACR 2026 will provide an opportunity for the company to showcase its latest advancements and engage with the broader oncology community. The insights and collaborations that emerge from the conference may help drive further innovation and progress in the field of precision cancer care.